메뉴 건너뛰기




Volumn 82, Issue 1, 2008, Pages 127-131

The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control

Author keywords

ARB; Hypertension; Insulin resistance; Type 2 diabetes

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOSARTAN; LOW DENSITY LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; TELMISARTAN; TRIACYLGLYCEROL; VALSARTAN;

EID: 52949146330     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.07.003     Document Type: Article
Times cited : (21)

References (25)
  • 1
    • 0032511580 scopus 로고    scopus 로고
    • Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
    • UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
    • (1998) BMJ , vol.317 , pp. 703-713
    • UK Prospective Diabetes Study Group1
  • 2
    • 3142781955 scopus 로고    scopus 로고
    • Prevention of type 2 diabetes mellitus through inhibition of the rennin-angiotensin system
    • Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the rennin-angiotensin system. Drugs 64 (2004) 2537-2565
    • (2004) Drugs , vol.64 , pp. 2537-2565
    • Scheen, A.J.1
  • 3
    • 0037160968 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol
    • Dahlof B., et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 995-1003
    • (2002) Lancet , vol.359 , pp. 995-1003
    • Dahlof, B.1
  • 4
    • 18544376399 scopus 로고    scopus 로고
    • Risk of new-onset diabetes in the Losartan intervention for endpoint reduction in hypertension study
    • Lindholm L.H., et al. Risk of new-onset diabetes in the Losartan intervention for endpoint reduction in hypertension study. J. Hypertens. 20 (2002) 1879-1886
    • (2002) J. Hypertens. , vol.20 , pp. 1879-1886
    • Lindholm, L.H.1
  • 5
    • 0042410539 scopus 로고    scopus 로고
    • Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme
    • Pfeffer M.A., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 362 (2003) 759-766
    • (2003) Lancet , vol.362 , pp. 759-766
    • Pfeffer, M.A.1
  • 6
    • 2942635317 scopus 로고    scopus 로고
    • Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial
    • Julius S., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363 (2004) 2022-2031
    • (2004) Lancet , vol.363 , pp. 2022-2031
    • Julius, S.1
  • 7
    • 1542547460 scopus 로고    scopus 로고
    • Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
    • Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
    • (2004) Hypertension , vol.43 , pp. 993-1002
    • Benson, S.C.1    Pershadsingh, H.A.2    Ho, C.I.3    Chittiboyina, A.4    Desai, P.5    Pravenec, M.6
  • 8
    • 10344249378 scopus 로고    scopus 로고
    • Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the rennin-angiotensin system
    • Kurtz T.W., and Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the rennin-angiotensin system. J. Hypertens. 22 (2004) 2253-2261
    • (2004) J. Hypertens. , vol.22 , pp. 2253-2261
    • Kurtz, T.W.1    Pravenec, M.2
  • 9
    • 0030994947 scopus 로고    scopus 로고
    • The homeostasis model in the San Antonio Heart Study
    • Haffner S.M., Miettinen H., and Stern M.P. The homeostasis model in the San Antonio Heart Study. Diabetes Care 20 (1997) 1087-1092
    • (1997) Diabetes Care , vol.20 , pp. 1087-1092
    • Haffner, S.M.1    Miettinen, H.2    Stern, M.P.3
  • 10
    • 33646590317 scopus 로고    scopus 로고
    • Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients
    • Furuta M., Tamai M., Hanabusa T., Yamamoto Y., Nanjo K., and Sanke T. Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients. Diab. Res. Clin. Pract. 72 (2006) 302-307
    • (2006) Diab. Res. Clin. Pract. , vol.72 , pp. 302-307
    • Furuta, M.1    Tamai, M.2    Hanabusa, T.3    Yamamoto, Y.4    Nanjo, K.5    Sanke, T.6
  • 11
    • 1842537144 scopus 로고    scopus 로고
    • Insulin-sensitizing effects of telmisartan; Implications for treating insulin-resistant hypertension and cardiovascular disease
    • Kurtz T.W. Insulin-sensitizing effects of telmisartan; Implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 27 (2004) 1015
    • (2004) Diabetes Care , vol.27 , pp. 1015
    • Kurtz, T.W.1
  • 12
    • 14644444519 scopus 로고    scopus 로고
    • Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes
    • Miura Y., Yamamoto N., Tsunekawa S., Taguchi S., Eguchi Y., Ozaki N., et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes. Diabetes Care 28 (2005) 757-758
    • (2005) Diabetes Care , vol.28 , pp. 757-758
    • Miura, Y.1    Yamamoto, N.2    Tsunekawa, S.3    Taguchi, S.4    Eguchi, Y.5    Ozaki, N.6
  • 13
    • 12844262135 scopus 로고    scopus 로고
    • Possible beneficial effect of telmisartan on glycemic control in diabetic subjects
    • Honjo S., Nishi Y., Wada Y., Hamamoto Y., and Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 28 (2005) 498
    • (2005) Diabetes Care , vol.28 , pp. 498
    • Honjo, S.1    Nishi, Y.2    Wada, Y.3    Hamamoto, Y.4    Koshiyama, H.5
  • 15
    • 0035989093 scopus 로고    scopus 로고
    • Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes
    • Luzio S.D., Dunseath G., and Owens D.R. Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes. Horm. Metab. Res. 34 (2002) 271-274
    • (2002) Horm. Metab. Res. , vol.34 , pp. 271-274
    • Luzio, S.D.1    Dunseath, G.2    Owens, D.R.3
  • 16
    • 3042732493 scopus 로고    scopus 로고
    • Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance
    • Anan F., Takahashi N., Ooie T., Hara M., Yoshimatsu H., and Saikawa T. Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism 53 (2004) 777-781
    • (2004) Metabolism , vol.53 , pp. 777-781
    • Anan, F.1    Takahashi, N.2    Ooie, T.3    Hara, M.4    Yoshimatsu, H.5    Saikawa, T.6
  • 17
    • 2442451618 scopus 로고    scopus 로고
    • Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γactivity
    • Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γactivity. Circulation 109 (2004) 2054-2057
    • (2004) Circulation , vol.109 , pp. 2054-2057
    • Schupp, M.1    Janke, J.2    Clasen, R.3    Unger, T.4    Kintscher, U.5
  • 18
    • 0842313004 scopus 로고    scopus 로고
    • Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients
    • Bajaj M., Suraamornkul S., Piper P., Hardies L.J., Glass L., Cersosimo E., et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J. Clin. Endocrinol. Metab. 89 (2004) 200-206
    • (2004) J. Clin. Endocrinol. Metab. , vol.89 , pp. 200-206
    • Bajaj, M.1    Suraamornkul, S.2    Piper, P.3    Hardies, L.J.4    Glass, L.5    Cersosimo, E.6
  • 19
    • 0036789137 scopus 로고    scopus 로고
    • The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects
    • Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
    • (2002) Diabetes , vol.51 , pp. 2968-2974
    • Yu, J.G.1    Javorschi, S.2    Hevener, A.L.3    Kruszynska, Y.T.4    Norman, R.A.5    Sinha, M.6
  • 20
    • 33644781780 scopus 로고    scopus 로고
    • Angiotensin II type receptor blockade improves β-cell function and glucose tolerance in a mouse model of type 2 diabetes
    • Chu K.Y., Lau T., Carlsson P.-O., and Leung P.S. Angiotensin II type receptor blockade improves β-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55 (2006) 367-374
    • (2006) Diabetes , vol.55 , pp. 367-374
    • Chu, K.Y.1    Lau, T.2    Carlsson, P.-O.3    Leung, P.S.4
  • 21
    • 6344258928 scopus 로고    scopus 로고
    • An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes
    • Fujimoto M., Masuzaki H., Tanaka T., Yasue S., Tomita T., Okazawa K., et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 576 (2004) 492-497
    • (2004) FEBS Lett. , vol.576 , pp. 492-497
    • Fujimoto, M.1    Masuzaki, H.2    Tanaka, T.3    Yasue, S.4    Tomita, T.5    Okazawa, K.6
  • 22
    • 12444273748 scopus 로고    scopus 로고
    • Distinct properties and advantages of a novel peroxisome proliferator-activated protein (γ) selective modulator
    • Berger J.P., Petro A.E., Macnaul K.L., Kelly L.J., Zhang B.B., Richards K., et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein (γ) selective modulator. Mol. Endocrinol. 17 (2003) 662-676
    • (2003) Mol. Endocrinol. , vol.17 , pp. 662-676
    • Berger, J.P.1    Petro, A.E.2    Macnaul, K.L.3    Kelly, L.J.4    Zhang, B.B.5    Richards, K.6
  • 23
    • 33644672013 scopus 로고    scopus 로고
    • Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity
    • Schupp M., Clemenz M., Gineste R., Witt H., Janke J., Helleboid S., et al. Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 54 (2005) 3442-3452
    • (2005) Diabetes , vol.54 , pp. 3442-3452
    • Schupp, M.1    Clemenz, M.2    Gineste, R.3    Witt, H.4    Janke, J.5    Helleboid, S.6
  • 24
    • 33646148948 scopus 로고    scopus 로고
    • Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis
    • Sugimoto K., Qi N.R., Kazdova L., Pravenec M., Ogihara T., and Kurtz T.W. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47 (2006) 822-823
    • (2006) Hypertension , vol.47 , pp. 822-823
    • Sugimoto, K.1    Qi, N.R.2    Kazdova, L.3    Pravenec, M.4    Ogihara, T.5    Kurtz, T.W.6
  • 25
    • 0032505096 scopus 로고    scopus 로고
    • Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
    • Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395 (1998) 137-143
    • (1998) Nature , vol.395 , pp. 137-143
    • Nolte, R.T.1    Wisely, G.B.2    Westin, S.3    Cobb, J.E.4    Lambert, M.H.5    Kurokawa, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.